Head-to-head · Value Score
CoreAge Rx vs ShedRx
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, ShedRx a 86. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-nameShedRx
#15 · Grade A- · Great Deal
Est. first month
$199/mo
Save ~85% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 86 — an est. $149/mo first month, with no teaser step-up baked in. ShedRx isn't out of it: Shoppers who want a low tirzepatide price or a lower-cost oral option instead of weekly injections.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | ShedRx |
|---|---|---|
| Value Score | 93 (A+) | 86 (A-) |
| Est. first month | $149/mo | $199/mo |
| Save vs brand-name | ~89% | ~85% |
| Semaglutide | $149/mo | $199/mo |
| Tirzepatide | $349/mo | $299/mo |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | All 50 states | Not disclosed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
ShedRx
One of the better tirzepatide deals, plus a cheaper oral/sublingual route for the needle-averse.
Why it's a deal
- Competitive $299 tirzepatide — cheaper than most flat-fee rivals
- Offers oral/sublingual forms at a lower entry price
- Both molecules available
The fine print
- States-served list not disclosed
- Compounded only — no brand-name access
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.